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ABBREVIATIONS
Ar Aromatic
DM Diabetes millitus 
AR Aldose reductase
ROS Reactive Oxidative Stress
NADPH Nicotinamide  adenine  di  nucleotide
phosphate
e.g. Example
% Percentage
1HNMR Nuclear Magnetic Resonance
Mg Milligram
Ml Milliliter
µg Microgram
mm Millimeter
w/w Weight by weight
v/v Volume by volume
µg/ml Microgram per liter
Hrs Hours
0C Degree centigrade
Fig. Figure
Tab. Table
UV-VIS Ultraviolet and visible spectroscopy
min. Minutes
IR Infrared spectroscopy
Std Standard
TLC Thin layer chromatography
KBr Potassium bromide
FTIR Fourier transform infrared spectrometer
IC Inhibitory concentration
EC Effective concentration
Cont Control
DMSO Dimethyl sulfoxide
DPPH                    Diphenylpicrylhydrazyl
FRAP Ferric reducing antioxidant power assay
Compound code IUPAC name
A1 4-(1-(diethylamino)ethyl)-2-methyloxazol-5(4H)-onE
A2 4-((diethylamino)(4-methoxyphenyl)methyl)-2-methyloxazol-5(4H)-one
A3 4-((diethylamino)(phenyl)methyl)-2-methyloxazol-5(4H)-one
A4 4-(1-(diethylamino)-3-phenylallyl)-2-methyloxazol-5(4H)-one
A5 4-((diethylamino)(2-chlorophenyl)methyl)-2-methyloxazol-5(4H)-one
A6 4-((diethylamino)(4-(dimethylamino)phenyl)methyl)-2-methyloxazol-
5(4H)-one
B1 2-benzyl-4-(1-(diethylamino)ethyl)oxazol-5(4H)-one
B2 4-((diethylamino)(4-methoxyphenyl)methyl)-2-benzyloxazol-5(4H)-one
B3 4-((diethylamino)(phenyl)methyl)-2-benzyloxazol-5(4H)-one
B4 2-benzyl-4-(1-(diethylamino)-3-phenylallyl)oxazol-5(4H)-one
B5 4-((diethylamino)(2-chlorophenyl)methyl)-2-benzyloxazol-5(4H)-one
B6 4-((diethylamino)(3-chlorophenyl)methyl)-2-benzyloxazol-5(4H)-one
B7 4-((diethylamino)(4-(dimethylamino)phenyl)methyl)-2-benzyloxazol-
5(4H)-one
B8 4-((diethylamino)(4-hydroxyphenyl)methyl)-2-benzyloxazol-5(4H)-one
Abstract
Diabetes  mellitus  (DM)  is  a  major  degenerative  disease  in  the  world  today.  Several
epidemiological and clinical studies indicate a direct relationship between hyperglycemia and
long-term  complications  such  as  retinopathy,  nephropathy,  neuropathy  and  various  fungal
infections  etc.  This  study  was  undertaken  to  evaluate  the  activity  of  some  Novel  Michael
Addition derivatives of 2,4-disubstituted Oxazol-5(4H)-one derivatives against Diabetes and its
complications  by  using  in  vitro enzyme  inhibition  technique.  These  derivatives  showed
considerable biological efficacy when compared to pioglitazone, a potent and well known anti
diabetic agent as a reference drug. All the compounds were effective, amongst them di methyl
amino  benzaldehyde  (A6  and  B7)  and  acetaldehyde  derivatives  (A1  and  B1)  shown  more
prominent activity. 
Key words: Oxazolone scaffold; retinopathy; neuropathy and nephropathy .
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INTRODUCTION
Diabetes mellitus  1,2 (DM) is a major degenerative disease in the world today. Several
epidemiological and clinical  studies indicate a direct relationship between hyperglycemia and
long-term complications such as retinopathy, nephropathy, neuropathy and angiopathy etc. India
has  today become the  diabetic  capital  of  the  world  with  over  20  million  diabetics  and  this
number  is  set  to  increase  to  57  million  by  2025.DM  is  a  multifactorial  disease  which  is
characterized by hyperglycemia ,lipoprotein abnormalities, raised basal metabolic rate, defect in
reactive  oxygen  species  scavenging  enzymes and  high  oxidative  stress-induced  damage  to
pancreatic beta cells. It is ranked seventh among the leading causes of death and is considered
third when its fatal complications are taken into account.
The term DM describes  a  metabolic  disorder  of    aetiology characterized by chronic
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from
defects in insulin secretion, insulin action, or both. The effects of diabetes mellitus include long–
term damage, dysfunction and failure of various organs.  Diabetes  mellitus may present  with
characteristic symptoms such as thirst, polyuria, blurring of vision, and weight loss. In
its most severe forms, ketoacidosis or a non– ketotic hyperosmolar state may develop and lead to
stupor, coma and, in absence of effective treatment, death. Often symptoms are not severe, or
may be absent, and consequently hyperglycaemia sufficient to cause pathological and functional
changes may be present for a long time before the diagnosis is made. The long–term effects of
diabetes mellitus include progressive development of the specific complications of retinopathy
with potential blindness, nephropathy that may lead to renal failure, and/or neuropathy with risk
of  foot  ulcers,  amputation,  Charcot  joints,  and features  of  autonomic  dysfunction,  including
sexual  dysfunction.  People  with  diabetes  are  at  increased  risk  of  cardiovascular,  peripheral
vascular and cerebrovascular disease.
Based on the aetiology DM is classified into different types they are, 
1. Type 1 
2. Type 2 and 
3. Gestational diabetes
TYPE 1 3:
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Type 1 diabetes occurs in about 10-15% of all cases of diabetes.  It  usually occurs in
people under the age of 30, but can happen at any age.
Type  1  indicates  the  processes  of  beta–cell  destruction  that  may  ultimately  lead  to
diabetes  mellitus  in  which  “insulin  is  required  for  survival”  to  prevent  the  development  of
ketoacidosis, coma and death. An individual with a Type 1 process may be metabolically normal
before the disease is clinically manifest, but the process of beta–cell destruction can be detected.
Type 1 is  usually characterized by the presence of anti–GAD, islet  cell or insulin antibodies
which identify the autoimmune processes that lead to beta–cell destruction. In some subjects
with this clinical form of diabetes, particularly non–Caucasians, no evidence of an autoimmune
disorder  is  demonstrable  and  these  are  classified  as  “Type  1  idiopathic”.  Aetiological
classification may be possible in some circumstances and not in others. Thus, the aetiological
Type 1 process can be identified and sub–categorized if appropriate antibody determinations are
performed. It is recognized that such measurements may be available only in certain centres at
the  present  time.  If  these  measurements  are  performed,  then  the  classification  of  individual
patients should reflect this.
TYPE 2 3,4:
Type 2 diabetes has emerged recently as a problem among adolescents and young adults,
particularly in high-prevalence populations. Although type 1 diabetes remains the
most prevalent form of the disease in children worldwide, it is likely that type 2 diabetes will be
the predominant form within 10 years in many populations. Type 2 diabetes has already been
reported in children from Japan, the Pacific Islands, Hong Kong, Singapore, China, Malaysia,
Korea and Australia. Among children in Japan, it is already more common than type 1 diabetes,
accounting for 80% of childhood diabetes; the incidence has almost doubled between 1976–80
and 1991–95.
Initially insulin is still produced by the pancreas, but is less effective than normal. This is
called insulin resistance and is an inherited characteristic made worse by carrying extra body fat.
Because insulin is necessary for glucose to move from the blood stream into the body cells and
the liver,  excess  glucose remains  in  the blood stream resulting in  higher  than normal  blood
glucose levels (BGLs). After several years of diabetes, the pancreas may become “exhausted”
and produce less insulin.
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GESTATIONAL DIABETES 5,6:
Gestational diabetes is carbohydrate intolerance resulting in hyperglycaemia of variable
severity with onset or first recognition during pregnancy. It does not exclude the possibility that
the  glucose  intolerance  may antedate  pregnancy but  has  been  previously unrecognized.  The
definition applies irrespective of whether or not insulin is used for treatment or the condition
persists after pregnancy. Women who become pregnant and who are known to have diabetes
mellitus which antedates pregnancy do not have gestational diabetes but have “diabetes mellitus
and pregnancy” and should be treated accordingly before, during, and after the pregnancy.
In  the  early part  of  pregnancy (e.g.  first  trimester  and first  half  of  second  trimester)
fasting  and  postprandial  glucose  concentrations  are  normally  lower  than  in  normal,  non–
pregnant  women.  Elevated  fasting  or  postprandial  plasma  glucose  levels  at  this  time  in
pregnancy may well reflect the presence of diabetes which has antedated pregnancy, but
Criteria for designating abnormally high glucose concentrations at this time have not yet been
established. The occurrence of higher than usual plasma glucose levels at this time in pregnancy
mandates careful management and may be an indication for carrying out an OGTT (Annex 1).
Nevertheless, normal glucose tolerance in the early part of pregnancy does not itself establish
that gestational diabetes may not develop later.
OTHER SPECIFIC TYPES OF DIABETES 6:
1. Genetic defects of beta-cell function
2. Genetic defects in insulin action
3.  Diseases of the exocrine pancreas
4. Endocrinopathies
5. Drug- or chemical-induced
6. Infections
7. Uncommon forms of immune-mediated diabetes
8. Other genetic syndromes Sometimes Associated with Diabetes
Diagnostic Procedure:
 Random blood glucose test — for a random blood glucose test, blood can be drawn at
any time throughout the day, regardless of when the person last ate. A random blood
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glucose level of 200 mg/dL (11.1 mmol/L) or higher in persons who have symptoms of
high blood glucose suggests a diagnosis of diabetes.
 Fasting blood glucose test  — fasting blood glucose testing involves measuring blood
glucose  after  not  eating or  drinking for  8  to  12  hours  (usually overnight).  A normal
fasting blood glucose level is less than 100 mg/dL. A fasting blood glucose of 126 mg/dL
(7.0 mmol/L) or higher indicates diabetes. The test is done by taking a small sample of
blood from a vein or fingertip.  It  must be repeated on another day to confirm that  it
remains abnormally high.
 Hemoglobin A1C test (A1C) — The A1C blood test measures the average blood glucose
level during the past two to three months. It is used to monitor blood glucose control in
people  with  known  diabetes,  but  is  not  normally  used  to  diagnose  diabetes.  Normal
values for A1C are 4 to 6 percent. The test is done by taking a small sample of blood
from a vein or fingertip.
 Oral glucose tolerance test — Oral glucose tolerance testing (OGTT) is the most sensitive
test  for  diagnosing  diabetes  and  pre-diabetes.  However,  the  OGTT  is  not  routinely
recommended because it is inconvenient compared to a fasting blood glucose test.
 Tab1:Diagnostic criteria for diabetes and pre-diabetes (non-pregnant adults)
Normal
1. Fasting plasma glucose <100 mg/dl. 
or 
2. Oral glucose tolerance test (OGTT) 2-hr plasma glucose <140 mg/dl. 
Pre-diabetes 
1. A1C range of 5.7–6.4%. 
or 
2. Impaired fasting glucose (IFG) = fasting plasma glucose of 100–125 mg/dl. 
3. Impaired glucose tolerance (IGT) = OGTT 2-hr plasma glucose of 140–199 mg/dl. 
Diabetes 
1. A1C >6.5%.  The test should be performed in a laboratory using a method that is certified by the
National Glycohemoglobin Standardization Program (NGSP) and standardized to the Diabetes Control
and Complications trial (DCCT) assay. 
or 
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2. Fasting plasma glucose >126 mg/dl. Fasting is defined as no caloric intake for at least eight hours. 
3. 2-h plasma glucose >200 mg/dl during an oral glucose tolerance test. The test should be performed
using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. 
4. Symptoms of diabetes and a casual plasma glucose >200 mg/dl. “Casual” is defined as any time of
day, without regard to the time since the last meal. The classic symptoms of diabetes include polyuria,
polydipsia, and unexplained weight loss. 
Treatment:
Tab 2: Summary of Antidiabetic interventions as monotherapy for type 2 diabetes:
Tab 3:Newer derivatives for Diabetes treatment:
Anti- Diabetic Agents Biological effects
Thiazolidinone  substituted  biphenyl  scaffold
derivatives
• Increases IRb tyrosine
          Phosphorylation
• Hypoglycemic
Benzylidene-2,4-thiazolidinedione derivatives
substituted at ortho position of the phenyl group
• Suppresses weight gain
• Hypoglycemic
K M C H College of pharmacy 5
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• Reduces circulating triglycerides,
• total cholesterol, and NEFA
5-(3-((Z)-((Z)-2-(4-chlorophenylimio)-4-
oxothiazolidin-5-ylidene)  methyl)-2,5  dimethyl-
1H-pyrrol-1-yl) isophthalic acid
• Competitive PTP1B inhibitor 
• Increases IRb tyrosine
• phosphorylation
Methylenedisalicylic acid derivatives • Improves glucose tolerance
• Reduces body weight, adipose
Isothiazolidinone  inhibitors  (imidazole  and
imidazoline analogs)
• hypoglycemic
4-[(5-Arylidene-4-oxo-2  phenyliminothiazolidin-
3-yl)methyl]-benzoic acids
• Lipophilic
• Improved cellular permeability
Monosodium({[5-(1,1-dimethylethyl)thiazol-2-
yl]methyl}{[(4-{4-[4-(1-
propylbutyl)phenoxy]methyl}phenyl)thiazol-2-
yl]methyl}amino)acetate
• Increases insulin-stimulated
• glucose uptake
1-Biphenyl-4-yl-2-(4-nitro-phenoxy)-ethanone • Acute and chronic hypoglycemic
activity
• Reduces  circulating
HbA1c,Triglycerides and LDL
Bidentate a-ketoacid–based inhibitors • Potential as therapeutics for diabetes
and obesity.
Triazole-linked glycosylated a-ketocarboxylic acid
derivatives
• Competitive inhibitor
Aryl diketoacid derivatives • Noncompetitive inhibitors
Difluoro-methylenephosphonate  bioisosteres  on a
sulfonamide scaffold
• PTP1B activity inhibitors
b-C-glycosiduronic  acids  quinones  and  b-C-
glycosyl compounds
• PTP1B activity inhibitor
2-(Oxalylamino) benzoic acid • Predictive high biological activities
Benzofuran and benzothiophene biphenyls (BBB) • hypoglycemic
Substituted phenoxy-3-piperazin-1-yl-propan-2-ols • Hypoglycemic
Thiophene derivatives • Permeable to cell membranes 
• Increases Akt phosphorylation
2-(4-Methoxyphenyl) ethyl] acetamide derivatives • Hypoglycemic 
Mixed-ligand  oxovanadium(IV)  complexes
Chemical synthesis
• Potential insulin-enhancing agent
INTA • Highly selective PTP1B inhibitor
INTB • Highly selective PTP1B inhibitor
Diabetes can affect almost all body parts including eyes, kidneys, feet,  nerves, heart and
skin. Chronic diabetes can give rise to several life-threatening complications such as increased
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risk  of  developing  bone  and  joint  disease,  stroke,  nervous  system disorder,  infection  of  the
respiratory system, kidney disease, hypertension, heart disease and visual impairment and loss of
digits or limbs.
Diabetes  may  remain  unnoticed  for  many  years  until  these  complications  manifest
themselves. That is why diabetes is known as the 'Silent Killer'.
Diabetes can give rise to several skin conditions, including bacterial infections such as
sties,  boils  and  carbuncles;  fungal  infections  such  as  Candidiasis;  and  dry,  itchy skin.  High
glucose levels in the blood can enhance the growth of fungi and skin is the flourishing site for it.
Tinea pedis occurring between the toes and sometimes the fingers is most frequently caused by
Trichophyton mentagrophytes and Trichophyton rubrum. Candida albicans is another common
fungus that causes skin infections and it most commonly affects the vaginal and groin areas.
Three other common fungal infections are athlete's foot (affecting the skin between the
toes), jock itch (red, itchy area on the genitals as well as inside of the thighs) and ringworm
(ring-shaped, itchy, scaly patches or blisters that can appear on groin, feet, abdomen, chest and
scalp or nails). Itching, blistering, swelling and dry flaky skin or severe scaling are the common
symptoms of fungal infections.
ANTIOXIDANT 
FREE RADICAL FORMATION
Atoms are most stable in the ground state. An atom is considered to be "ground" when
every electron in the outermost shell has a complimentary electron that spins in the opposite
direction.  By definition a  free  radical  is  any atom (e.g.  oxygen,  nitrogen) with  at  least  one
unpaired electron in the outermost shell, and is capable of independent existence . A free radical
is easily formed when a covalent bond between entities is broken and one electron remains with
each  newly formed atom.  Free  radicals  are  highly reactive due  to  the  presence  of  unpaired
electron(s). The following literature review addresses only radicals with an oxygen center. Any
free radical  involving oxygen can be referred to as reactive oxygen species  (ROS).  Oxygen
centered free radicals contain two unpaired electrons in the outer shell. When free radicals steal
an electron from a surrounding compound or molecule a new free radical is formed in its place.
In turn the newly formed radical then looks to return to its ground state by stealing electrons with
antiparallel spins from cellular structures or molecules. Thus the chain reaction continues and
can be "thousand of events long."  The electron transport chain (ETC), which is found in the
inner  mitochondrial  membrane,  utilizes  oxygen  to generate  energy in  the form of  adenosine
triphosphate (ATP). Oxygen acts as the terminal electron acceptor within the ETC. The literature
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suggests that anywhere from 2 to 5%  of the total oxygen intake during both rest and exercise
have the ability to form the highly damaging superoxide radical  via electron escape.  During
exercise  oxygen  consumption  increases  10 to  20  fold to  35-70  ml/kg/min.  In  turn,  electron
escape from the ETC is further enhanced. Thus, when calculated, .6 to 3.5 ml/kg/min of the total
oxygen intake during exercise has the ability to form free radicals. Electrons appear to escape
from the ETS at the ubiqunone-cytochrome c level.
PEROXIDATION
Polyunsaturated fatty acids (PUFAs) are abundant in cellular  membranes  and in low-
density lipoproteins (LDL). The PUFAs allow for fluidity of cellular membranes. A free radical
prefers to steal electrons from the lipid membrane of a cell, initiating a free radical attack on the
cell known as lipid peroxidation. Reactive oxygen species target the carbon-carbon double bond
of polyunsaturated fatty acids.  The double bond on the carbon weakens the carbon-hydrogen
bond allowing for easy dissociation of the hydrogen by a free radical. A free radical will steal the
single electron from the hydrogen associated with the carbon at the double bond. In turn this
leaves the carbon with an unpaired electron and hence becomes a free radical. In an effort to
stabilize the carbon-centered free radical molecular rearrangement occurs. The newly arranged
molecule is called a conjugated diene (CD). The CD then very easily reacts with oxygen to form
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a proxy radical. The proxy radical steals an electron from another lipid molecule in a process
called propagation.
TYPES OF FREE RADICALS
There are numerous types of free radicals that can be formed within the body. This web
site is only concerned with the oxygen centered free radicals or ROS. The most common ROS
include:  the  superoxide  anion  (O2-),  the  hydroxyl  radical  (OH-),  singlet  oxygen  (O2 ),  and
hydrogen  peroxide  (H2O2)  Superoxide  anions  are  formed  when  oxygen  (O2)  acquires  an
additional  electron,  leaving  the  molecule  with  only  one  unpaired  electron.  Within  the
mitochondria O2- · is continuously being formed. The rate of formation depends on the amount of
oxygen flowing through the mitochondria at any given time. Hydroxyl radicals are short-lived,
but the most damaging radicals within the body. This type of free radical can be formed from O2-
and H2O2 via the Harber-Weiss reaction. The interaction of copper or iron and H2O2 also produce
OH ·  as first observed by Fenton. These reactions are significant  as the substrates are found
within the body and could easily interact.  Hydrogen peroxide is  produced in  vivo by many
reactions.  Hydrogen  peroxide  is  unique  in  that  it  can  be  converted  to  the  highly damaging
hydroxyl radical  or be catalyzed and excreted harmlessly as water.  Glutathione peroxidase is
essential  for  the  conversion  of  glutathione  to  oxidized  glutathione,  during  which  H2O2 is
converted to water. If  H2O2 is not converted into water O2-  is formed. Singlet oxygen is not a
free radical, but can be formed during radical reactions and also cause further reactions. Singlet
oxygen violates Hund's rule of electron filling in that it has eight outer electrons existing in pairs
leaving one orbital of the same energy level empty. When oxygen is energetically excited one of
the electrons can jump to empty orbital creating unpaired electrons . Singlet oxygen can then
transfer  the  energy to  a  new molecule  and  act  as  a  catalyst  for  free  radical  formation.  The
molecule can also interact with other molecules leading to the formation of a new free radical.
An  antioxidant is  a  molecule capable of inhibiting the  oxidation of other molecules.
Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent.
Oxidation reactions can produce free radicals. In turn, these radicals can start chain reactions that
damage  cells.  Antioxidants  terminate  these  chain  reactions  by  removing  free  radical
intermediates, and inhibit other oxidation reactions. They do this by being oxidized themselves,
so antioxidants are often reducing agents such as thiols, ascorbic acid or polyphenols 17. 
Although oxidation reactions are crucial for life, they can also be damaging; hence, plants
and  animals maintain complex systems of multiple types of antioxidants, such as  glutathione,
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vitamin C, and vitamin E as well as enzymes such as catalase, superoxide dismutase and various
peroxidases.  Low  levels  of  antioxidants,  or  inhibition of  the  antioxidant  enzymes,  cause
oxidative stress and may damage or kill cells. As oxidative stress might be an important part of
many  human  diseases,  the  use  of  antioxidants  in  pharmacology is  intensively  studied,
particularly as treatments for  stroke and  neurodegenerative diseases.  However,  it  is unknown
whether oxidative stress is the cause or the consequence of disease.
Reactive oxygen species (ROS), capable of causing damage to DNA, has been associated
with  carcinogenesis,  coronary  heart  disease,  and  many  other  health  problems  related  to
advancing age 18. In low concentrations, synthetic antioxidants are also in use for many industrial
processes e.g.  inhibition of radical  formation for preventing premature polymerization during
processing,  storage  and  transportation  of  unsaturated  monomers.  They exert  their  effects  by
scavenging  or  preventing the  generation  of  ROS 19 which  can  protect  the  formation  of  free
radicals and retard the progress of many chronic diseases20 including cancer, neurodegenerative,
inflammation and cardiovascular diseases 21.
Fungus  24 is  a  member  of  a  large  group  of  eukaryotic organisms  that  includes
microorganisms such as  yeasts  and  mushrooms. These organisms are classified as a  kingdom,
Fungi. Abundant worldwide;  most fungi are inconspicuous because of the small size of their
structures, and their cryptic lifestyles in soil, on dead matter, and as symbionts of plants, animals,
or  other  fungi.  Fungi  can  break  down  manufactured  materials  and  buildings,  and  become
significant pathogens of humans and other animals. Losses of crops due to fungal diseases (e.g.
rice blast disease) or food  spoilage can have a large impact on human food supplies and local
economies. 
Pathogens and parasites 25, 26: 
Many fungi are parasites on plants, animals (including humans), and other fungi. Serious
pathogens of many cultivated plants causing extensive damage and losses  to agriculture and
forestry include the  rice blast fungus Magnaporthe oryzae, tree pathogens such as  Ophiostoma
ulmi and  Ophiostoma  novo-ulmi causing  Dutch  elm  disease,  and  Cryphonectria  parasitica
responsible for chestnut blight, and plant pathogens in the genera Fusarium, Ustilago, Alternaria,
and  Cochliobolus.  Some  carnivorous  fungi,  like  Paecilomyces  lilacinus,  are  predators of
nematodes, which they capture using an array of specialized structures such as constricting rings
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or adhesive nets. Some fungi can cause serious diseases in humans, several of which may be fatal
if  untreated.  These  include  aspergilloses,  candidoses,  coccidioidomycosis,  cryptococcosis,
histoplasmosis,  mycetomas,  and  paracoccidioidomycosis.  Furthermore,  persons with  immuno-
deficiencies are  particularly  susceptible  to  disease  by  genera  such  as  Aspergillus,  Candida,
Cryptoccocus,  Histoplasma,  and  Pneumocystis.  Other  fungi  can  attack  eyes,  nails,  hair,  and
especially skin, the so-called dermatophytic and keratinophilic fungi, and cause local infections
such as ringworm and athlete’s foot. Fungal spores are also a cause of allergies, and fungi from
different taxonomic groups can evoke allergic reactions.
Antibiotic resistance 27:
Antibiotic resistance is a type of drug resistance where a microorganism is able to survive
exposure to an antibiotic. Many antibiotic resistance genes reside on plasmids, facilitating their
transfer. If a bacterium carries several resistance genes, it is called multiresistant or, informally, a
superbug or super bacterium. The primary cause of antibiotic resistance is antibiotic use both
within medicine and veterinary medicine. The greater the duration of exposure the greater the
risk of the development of resistance irrespective of the severity of the need for antibiotics. As
resistance  becomes  more  common  there  becomes  a  greater  need  for  alternative  treatments.
However despite a push for new antibiotic therapies there has been a continued decline in the
number of newly approved drugs. Antibiotic resistance therefore poses a significant problem.
Causes for antibiotic resistance 27: 
 Antibiotic misuse 
 Resistant transmitted through animals.
Oxazole  28 is a five membered heterocyclic compound.  These are azoles with oxygen
and nitrogen separated by a carbon atom. The Oxazole ring system is not abundant in nature
although  there  are  number  of  macrocyclic  antibiotics  and  antifungal  agents  which  contain
oxazole nucleus. 
O
N
Eg., Griseovirdin and Helichondramide.
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Oxazolone  3 is a class of small heterocycles, which are important intermediates in the
synthesis of several small molecules, including amino acids, peptides, antimicrobial or antitumor
compounds  ,heterocyclic precursors  as  well  as  biosensors  coupling  and  or photosensitive
composition devices for proteins. Some Oxazolones have shown a wide range of pharmaceutical
properties.
In continuation of our drug discovery program, we synthesized a variety of oxazolones
and screened their effects on different aspects of diabetic response.
CHEMISTRY OF OXAZOLES
Methods of synthesis of Ox azoles:
Robinson – Gabriel synthesis 27:
The  Robinson  –  Gabriel  synthesis  is  a  named  reaction  used  to  synthesize  oxazoles  by
dehydrating acylamino-ketones. The dehydrating agents used are sulphuric acid or phosphorus
oxychloride.
R1
R2
O
O H
N H2SO4
O
N
R1 R2
Fischer Oxazole synthesis28:
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The  Fischer  oxazole  synthesis  is  a  chemical  synthesis  of  the  aromatic  heterocyclic
oxazole  from  cyanohydrins  and  aldehydes  in  the  presents  of  An.  HCl.  This  method  was
discovered by Hermen emil in 1896.
R1
OH
N R2 H
O O
N
R1 R2+
HCl
Van leusen oxazole synthesis29:
In this reaction the oxazoles are prepared from aldehydes by reaction with tosyl methyl
isocyanide.
R H
O
NCTos
N
O
R
K2CO3+
Oxazoles30 are formed via butanol or iodine mediated doimino oxidative cyclization from
readily available starting materials under mild conditions.
Ar +H2N Ar1 O
N
Ar1 Ar2
BuOOH
I2
Di  substituted  oxazoles  31 were  formulated  via  Iodine  catalyzed  tanden  oxidative
cyclization method at 110 0C by using DMSO as a solvent.
R NH2
O
+ Br
Br Cs2CO3
N
O
R
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Oxazoles  32 were prepared by Cs2CO3  mediated reaction of aromatic and unsubstituted
primary amides with 2, 3 di bromo propene. This leads to the synthesis of 2- aryl – 5- alkyl
substituted oxazoles in a single step.
R NH2
O
+ Br
Br Cs2CO3
N
O
R
Oxazoles  33  were  formulated  by  cyclization  of  propyl  alcohols  with  anilines  in  the
presents of  Zn(OTf)2  catalyst, at 100 0C without additives.
HO
Ar +
NH2
R
O ToRuPPh3(CH3CN)2PF6
O
N
Ar R
Zn(OTf)2
+
Tri  substituted  Oxazoles  34 were  prepared  by  copper  catalysed  tandem  oxidative
cyclization by using DMSO as a solvent.
Ar NH2 + R R1
O O Cu(OAc) N
OAr R
R
O
Substituted cyanoamides produces tri  substituted oxazoles35 in the presence of lithium
bromide, by using toluene as a solvent.
R'
Ph
NC
O R
+ R'' H
O
LiBr N
ON
Ph
R'
R''
OH
R
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Double acylation of  a  protected glycine  affords  intermediate  amino keto ester,  which
inturn can be dehydrated to form 1,3 oxazoles 36.
R COOBu
O O R' PPh3
N
O
R'
R COOH
CHEMICAL PROPERTIES 3, 28:
Oxazole is a very weak base and its salts are unstable . N-alkyloxazolium salts have been
formed  from  several  substituted  oxazoles.  These  salts  easily  undergo  hydrogen  deuterium
exchange at C2 position.
Neutral  oxazoles  are  deprotonated  preferentially  at  C2  by  strong  bases.   2  methyl
substituents in oxazoles were activated by C=N bonds of the ring systems and these groups can
be  deprotonated  by alkyl-lithium reagents  and  strong  bases.  Oxazolythinium derivatives  are
thermally unstable and undergo reversible ring opening.
O
N
CHO
Me2NCHO
O
N
LiOLi
NC
OSiMe3
NCMe2SiCl
Electrophilic aromatic substitution:
Nitration:
Oxazole undergoes Electrophilic aromatic substitution at C5 position. The nitrating mixture used
is nitric acid and sulphuric acid.
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N
O
N
O NO2
HNO3
H2SO4
5-nitrooxazole
Sulphonation:
Oxazole undergoes sulphonation at C2 positon. The sulphonating agent used is sulphuric
acid.
N
O
N
O SO3H
H2SO4
oxazole-5-sulfonic acid
Halogenaton:
Oxazole undergoes halogenaton at C2 position. The reagents used are chlorine, bromine
etc.
N
O
N
O Cl
Cl2
5-chlorooxazole
N
O
N
O Br
Br2
5-bromooxazole
Friedel crafts alkylation:
Oxazole undergoes Friedel crafts alkylation at C2 position. Lewis acid like aluminum
chloride is used as catalyst and the reagent used is alkyl halides.
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N
O
N
O CH3
CH3Cl
5-methyloxazole
Friedel crafts acylation:
Oxazole undergoes  Friedel  crafts  acylation at  C2 position.  Lewis acid like aluminum
chloride is used as catalyst and the reagent used is acyl halides.
N
O
N
O COCH3
CH3COCl
5-Acyloxazole
Nucleophilic Aromatic substitution:
Oxazoles undergoes Nucleophilic Aromatic substitution at C2 position and form 2-nitro
oxazole, as well as 2-hydroxy oxazole. The catalyst used for this is cupper sulphate.
N
O
N
OCl HO
N
O
N
OCl H2N
hydroxylaton
CuSO4
Aq.NH3
oxazol-2-ol
oxazol-2-amine
2-chlorooxazole
2-chlorooxazole
Michael addition:
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As originally defined by Arthur Michael, the reaction is the addition of an enolate of a
ketone  or  aldehyde  to  an  α  ,  β-unsaturated  carbonyl  compound  at  the  β  carbon.  A newer
definition, proposed by Kohler, is the 1,4-addition of a doubly stabilized carbon nucleophile to
an α,β-unsaturated carbonyl compound. Some examples of nucleophiles include beta-ketoesters, 
malonates, and beta-cyanoesters. The resulting product contains a highly useful 1,5-dioxygenated
pattern.
The Michael addition is an important atom-electronic method for diastereoselective and
enantioselective C-C bond formation.
Mechanism:
Deprotonation of 1 by  base  leads  to carbanion 2 stabilized  by  its  electron-withdrawing
groups. Structures 2a to 2c are three resonance structures that can be drawn for this species, two
of which have  enolate ions. This nucleophile reacts with the electrophilic alkene 3 to form 4 in
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a conjugate  addition  reaction.  Proton  abstraction  from  protonated  base  (or  solvent)  by  the
enolate 4 to 5 is the final step.
The  course  of  the  reaction  is  dominated  by  orbital,  rather  than  electrostatic,
considerations. The HOMO of stabilized enolates has a large coefficient on the central carbon
atom  while  the LUMO of  many  alpha,  beta  unsaturated  carbonyl  compounds  has  a  large
coefficient  on  the  beta  carbon.  Thus,  both  reactants  can  be  considered soft.  These
polarized frontier  orbitals are  of  similar  energy,  and  react  efficiently  to  form a  new carbon-
carbon bond.
Like the aldol addition, the Michael reaction may proceed via an enol, silyl enol ether in
the Mukaiyama-Michael addition, or more usually, enolate nucleophile. In the latter case, the
stabilized  carbonyl  compound  is deprotonated with  a  strong  base  (hard  enolization)  or  with
a Lewis  acid and  a  weak  base  (soft  enolization).  The  resulting  enolate  attacks  the
activated olefin with 1,4-regioselectivity, forming a carbon-carbon bond. This also transfers the
enolate to the electrophile. Since the electrophile is much less acidic than the nucleophile, rapid
proton transfer usually transfers the enolate back to the nucleophile if the product is enolizable;
however, one may take advantage of the new locus of nucleophilicity if a suitable electrophile is
pendant. Depending on the relative acidities of the nucleophile and product, the reaction may
be catalytic in base. In most cases, the reaction is irreversible at low temperature, due to least-
motion arguments.
Erlenmeyer condition76:
Erlenmeyer  condition  is  use  full  for  the  synthesis  of  α  amino  acids.  Accroding  to
Erlenmeyer condition, the Oxazolones were prepared by condensation of hippuric acid or acetyl
glycine with aldehydes.
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ANTI-DIABETIC AGENTS
1. G.Mariappan et al.,1 synthesized aryl furano oxazolone derivatives as potent anti-
diabetic agents and these are having thyrosine Phosphatase inhibiting action.
O
O
N
OCH3
O
2. Harikishore Pingali et al., 47 synthesized oxazole containing 1,3-Dioxane-2-carboxylic 
acid derivatives as anti-diabetic agents by PPAR agonist action.
N OH
OO
O
N
O
O O
3. Atul Kumar et al.,48 synthesized 2-aryl-naphtho[1,2-d]oxazole derivatives and exhibited 
anti-diabetic agents by its potential PTP-1B inhibitor activty.
R2
OR1
NO
F3C
4. Masao Shiozaki et al.,49 synthesized tetrahydropyrano[2,3-d]oxazole and shown  potent 
anti-diabetic agents.
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O
N
NH
OH
HO
HO
OH
O
HO
HO OH
OH
ANTI-MICROBIAL AGENTS
5. Fumike  miyake  et  al.,54 synthesized 5-(3-indolyl)oxazole  derivatives,  a  potent  anti-
bacterial agents acting on both gram + and gram - microorganisms.
N
H
O
N
N
6. Salah Belaidi et al.,55 synthesized 2,4,5 tri substituted derivatives, a 
potent anti bacterial agents. All analogs shown moderate to good anti-
bacterial activity. 
N
OR1
R2
R3
7. Chung kyu jaa et al.,56 synthesized  benzo[d]oxazole-4,7-diones, a potent anti-fungal 
agents. All analogs shown moderate to good anti-fungal activity. 
O
N
R3
R2
R1
O
O
ANTI-INFLAMMATORY AND ANALGESIC
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8. Paul  c.  Unangst  et  al.,39 synthesized  series  of  oxazole  derivatives  of  2,  6-ditert-
Butylphenol  shown potent  anti-inflammatory activity by inhibiting  lipoxygenase and
cyclooxygenase enzymes.
O
NH
O
9. Kim F. McClure et al.,40 synthesized series of triazolopyridine oxazole derivatives 
shown good analgesic activity by antagonizing action on  p38  receptors.
NN
N
O
NR1
R2
10. Richard J. Perner et al.,41 synthesized series of 4,5-disubstituted-2-arylamino oxazole
derivatives shown potent anti-inflammatory activity  by TRPV1 antagonist action.
N
O
CF3
R
11. M. Ravi Shashi Nayana et al.,42 synthesized series of  triazolopyridine oxazole 
derivatives shown anti-inflammatory activity by  p38 MAP kinase inhibitor action.
NN
N
O
N
R2
R1
CARDIOVASCULAR AGENTS
12. Shankar Swaminathan et al.,43 synthsized 2,5-disubstituted derivatives shown
potent cardiovascular activity as that of Ifetroban Sodium
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O
N COR1R
13. Jie Eun Lee et  al.,44 synthesized oxazole linked arylpiperazinylalkylamines  as potent
anti-hypertensive agents by calcium channel blocking action.
N
N
H
N O
N
R
14. Kumiko Takeuchi et al. 45 synthesized Phenyl Oxazole Derivatives as potent anti-anginal
agent by its Thromboxane Receptor Antagonism andThromboxane Synthase Inhibition activity.
COOH
O
N
N
H
N
O
15. Francoise et al., 46synthesized  Bicyclic Oxazolone Derivatives as potent Anti-
Angiogenic Agents.
O
N
O
Cl
O
O
O
ANTIBIOTICS
16. Mikael  Bergdahl  et  al.,50 Synthesized   Oxazole-  and  Diene-Containing  C9-C23
Fragment of the Type A Streptogramin as potent antibiotics.
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HO
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OH
17.  Masaki Kita et al.,51 synthesized tris-oxazole macrolactone derivatives  and acted as
macrolide antibiotics.
O
OO
O
O O
O O
N
O
CHO
HO
ANTI-TUMOR AGENTS
18. Xin hua lee et al.,52   synthesized Novel 2,4,5-trisubstituted oxazole derivatives, a novel
group of anticancer agents active on a multidrug resistant cell line. All analogs showed
in-vitro cytotoxic  activity  against  human  and  mureine  leukemia  cell  line.  And  also
showed in-vivo anti-leukemic activity.
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OCH3
H3CO OCH3
R2
S R1
19.  Vincent et  al.,53 synthesized 2-phenyl-oxazole-4-carboxamide  derivatives  and  shown
potent apoptosis inducer activty.
N
O
HN
O
O
IMMUNOMODULATORY AGENTS
20. David S millon et al.,57 synthesized phenyl-carboxyethyl-oxazole derivatives, a potent 
immunosuppressants as that of urocanic acid.
N O
COOEt
21. Rongze  Kuang  et  al.,58 synthesized  quinoline  linked  oxazole  derivatives,  a  potent
immunostimulants which are act as phosphodiesterase 4 inhibitors.
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N
O
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O N
R1 R2
22. Muhammad  A.  Mesaik  et  al.,59 synthesized  aryl-oxazolone  derivative,  a  potent
immunomodulatory agents, acted by T-cell proliferation.
N
O
O
R
R1
ANTI-OBESITY AGENTS
23. H.O.Ok et al.,60 synthesized Substituted Oxazole Benzenesulfonamides as Potent Human
Adrenergic Receptor Agonists.
N
H
N
N
H
O2
S
N
O
R
OH
24. Brijesh  kumar et  al.,61 synthesized dihydropyrazole  of  4S-(β)-3-(4-chlorophenyl)-N-
methyl-N0-  [(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1Hpyrazole-  1-
caboxamidine oxazole  as potent CB1 receptor antagonist.
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Cl
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O
O
ANTI-ALZHEIMER AGENTS
25. Hossein Razavi et al.,62 synthesized substituted aryl-carboxyl-oxazoles, a potent anti-
Alzheimer agent by acting on amyloidogenesis.
O
N
OH
Ar
R O
ANTI-TUBERCULAR AGENTS
26. Garrett C. Moraski et al.,63 synthesized oxazole benzyl esters, a potent anti-tubercular 
agent. The compounds were tested by in vivo mouse infection model.
N
O
OBn
OBn O
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Type 2 diabetes comprises 90% of people with diabetes around the world and is one of
the major public health challenges of the 21st century. The number of cases worldwide in 2000 is
estimated to be about 171 million and is projected to rise to 366 million in 2030. The World
Health  Organization  (WHO)  projects  that  without  urgent  action,  diabetes-related  deaths  will
increase by more than 50% in the next 10 years. Especially in upper-middle income countries,
diabetes deaths are projected to increase by over 80% between 2006 and 2015. This circumstance
results that the demand for medical care in type 2 diabetes will continue to increase. 
Over  the  past  decade,  there  has  been  substantial  interest  in  oxidative  stress  and  its
potential  role  in  diabetogenesis,  development  of  diabetic  complications,  atherosclerosis  and
associated  cardiovascular  disease.  Over  production  of  reactive  oxygen  and  nitrogen  species
(ROS/RNS) leads to lowered antioxidant defense and alterations of enzymatic pathways. This
contribute to endothelial, vascular and neurovascular dysfunction. 
High glucose levels in the blood of Diabeteic Patients can enhance the growth of fungi
and  skin  is  the  flourishing  site  for  it.  Fungal  microorganisms  cause  many  infections  like
Candidiasis, dry itchy skin, tinea pedis, athlete's foot, jock itch and ring worm. 
So  developing  a  drug  moiety  containing  anti-diabetic  activity,  anti-oxidant  and  anti-
fungal will be a relevant adjuvant pharmacotherapy. 
According  to  literature  review,  Oxazolone  derivatives  were  proven  to  be  promising
agents, showing good activity against diabetes and its complications.
Oxazolone is a versatile molecule responsible for various activities like Analgesic, Anti-
angiogenic, immunomodulatory, anti-fungal and Anti-tumor etc.
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Design of work:
 2, 4 Di substituted oxazole have attracted continuing interest because of their
varied  biological  activities  namely  anti-cancer,  anti-inflammatory,  anti-
fungal and antioxidant etc.
 Recently, growing lines of evidence have suggested that 2, 4 Di substituted
oxazole  derivatives  are  having  anti  diabetic  activity  similar  to  that  of
Thiazolidinediones.
 Thiazolidinediones  were  withdrawn  because  of  increased  risk  of
hepatotoxicity, a potent side effect which limits the use of these derivatives
as safe drug candidates. 
 With this background the aim of our work is to synthesize, some novel 2, 4
Disubstituted  oxazolone  derivatives  which  are  having  structure  similarity
with that of thiazolidinedione derivatives.
The objectives of the present work can be summarized as follows:
 Synthesis  of  some  novel  potential  derivatives  of  Oxazolone  derivatives  by  using
experimental procedure.
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 Characterization of synthesized compounds by various analytical techniques like TLC,
FT IR, NMR and Mass Spectral studies.
 Screening for anti-diabetic activity by using in-vitro Aldose reductase enzyme inhibition
assay technique.
 Screening for anti-oxidant activity by using in-vitro DPPH and FRAP method.
 Screening  for  anti-fungal  activity  against  fungal  organisms  like  Aspergillus  niger,
Aspergillus fumigatus, Aspergillus parasiticus  and  Candida albicans, by Disc diffusion
method and determination of Minimum inhibitory concentration (MIC) by serial dilution
method.
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SYNTHESIS OF SOME NOVEL MICHAEL ADDITION DERIVATIVES OF
OXAZOLONE DERIVATIVES 
STEP 1 64:
We synthesized various Oxazolone derivatives by using different starting materials like
acetyl glycine and Hippuric acid. Hippuric acid was purchased from Sigma-aldrich chemicals
and Acetyl glycine was prepared by using the below procedure.
Preparation of Acetyl glycine:
37.5 g (0.5M) of glycine was added to 150ml of water in a 500ml conical flask and
stirred vigorously with mechanical stirrer until the solid was completely dissolved. 102 gm of
(95  ml,  1M)  of  Acetic  anhydride  was  added  to  above mixture  for  15-20  min.  the  solution
becomes hot and some acetyl glycine was crystallized. Then the solution was kept in refrigerator
for overnight. The precipitate was separated on a Buchner funnel and washed with ice cold water
and dry at 1000C. 
STEP 2 64 :
General method for the preparation of 4-substituted-[Benzylidene]-2-(4-phenyl) oxazol-5-
one:
A mixture of Hippuric acid / Acetyl  glycine (0.01mol), substituted aromatic  aldehyde
(0.02mol), anhydrous sodium acetate (0.01 mol) and acetic anhydride (0.04mol) was refluxed for
1  h  on a  water  bath with  occasional  stirring.  The  resulting  mixture  was  left  in  refrigerator
overnight. The solid thus obtained was filtered, washed with cold water, dried in hot air oven at
60◦C and recrystallized from ethanol. All the  compounds were synthesized by adopting the same
procedure with variation in reaction time.
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STEP 3:
General method for preparation of Michael addition products65 :
Equal moles of Oxazolone derivatives were reacted with dietylamine by using 2M of
ceric ammonium nitrate as a catalyst. Heat the mixture on water bath for 5 - 60 minutes. All the
title compounds were synthesized by adopting the same procedure with variation in reaction
time.
The derivatives formed were recrystallized  by using suitable solvents like water and
DMSO.
The purity of the product was confirmed by a single spot on the TLC plate and solvent
system used was methanol: chloroform (1:1).Melting point was determined and uncorrected.
SCHEME 1:
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SCHEME 2:
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CODE R
A1                               CH3
A2
O
A3
                        
A4
            
A5
                       
Cl
A6
                       
N
B1                              CH3
B2
O
B3
                        
B4
            
B5
                       
Cl
B6
                       
N
B7
                       
Cl
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B8
                       
OH
CHARACTERIZATION OF THE SYNTHESIZED COMPOUNDS
MELTING POINT ANALYSIS 
Melting points of the synthesized compounds were determined in a one end fused capillary
tube method by using Thermonic Model –C-LMP- 1 CAMPVEEL melting point apparatus, and
were uncorrected.
THIN LAYER CHROMATOGRAPHY ANALYSIS
Purity of the compounds was checked by TLC using silica gel G (0.5mm thickness) coated over
glass plate (12 x 20 cm) as stationary phase, chloroform:methanol (1:1) as mobile phase and the spot was
visualized by iodine vapor. 
Log P:
The hydrophobic character of a drug can be measured experimentally by testing the drugs
relative distribution in an n-octanol/water mixture.
P=
concentrationof drug∈octanol
concentratio of drug∈aqueous solution
 SPECTRAL STUDIES66,67
ULTRA VIOLET SPECTRAL ANALYSIS
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The  maximum  absorbance  or   
λ
max
 of  synthesized  compounds  determined  in  the
concentration  of  0.01%  w/v  in  DMF  by  using  Shimadzu  2000  ultraviolet  Spectrophotometer.  The
maximum absorbance was measured in nm.
INFRARED SPECTRAL ANALYSIS
The  IR  Spectra  of  the  synthesized  compounds  were  recorded  by  JASCO-FT/IR  -1700
spectrophotometer in KBr disc. The IR value was measured in cm-1.
NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS
The NMR Spectra of the synthesized compounds were recorded by Bruker 300 MHz FT- NMR
using  TMS  (Tetramethylsilane)  as  internal  standard.  The  PMR  (Proton  Magnetic  Resonance)
spectroscopic values are measured in δ ppm in DMSO-d6.
MASS SPECTRAL ANALYSIS
The Mass Spectra of the synthesized compounds were recorded in MS (EI) JEOL GC
MATE 700 EV.
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ANTI-DIABETIC SCREENING OF THE SYNTHESIZED COMPOUNDS
BY USING IN VITRO ENZYME INHIBITON ASSAY TECHNIQUE
Procedure68 :
The Aldose reductase suspension was purchased from the sigma-aldrich. The AR activity
was spectrophotometrically assayed by measuring the decrease in NADPH absorption at 340 nm
over a 4 min period, using DL-glyceraldehyde as a substrate. Each 1.0 mL cuvette containing
equal units of enzyme, 0.1M sodium phosphate buffer (pH 6.2) and 0.3 mM NADPH either with
or without 10 mM substrate and inhibitor was prepared. One set of mixtures prepared with an
equivalent volume of sodium phosphate buffer instead of tested samples was used as control. The
concentration of the extracts required to inhibit 50% of ΑR activity under the assay conditions
was defined as the IC50 value. Pioglitazone was used as a standard drug. 
                           
                            A= Absorbance of sample
                            B= Absorbance of control 
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IN VITRO ANTI-OXIDANT SCREENING OF SYNTHESIZED 
COMPOUNDS
 In-vitro Anti-oxidant screening of synthesized compounds were done by using three 
methods 
 DPPH method
 FRAP method
Determination of DPPH (1-1-diphenyl 2-picryl hydrazyl) radical-scavenging 
activity:
Procedure69 :
The free radical-scavenging activity of  the synthesized compounds were measured in
terms of hydrogen donating or radical-scavenging ability using the stable radical DPPH. 0.1 mM
solution of DPPH in ethanol was prepared and 1.0 ml of this solution was added to 3.0 ml of
extract solution in methanol at different concentrations (25-100µg/ml). Thirty minutes later, the
absorbance was measured at 517 nm. Ascorbic acid was used as the reference compound. Lower
absorbance of  the reaction mixture indicated  higher  free  radical-scavenging activity.  Radical
scavenging activity was expressed as the inhibition percentage of free radical by the sample and
was calculated using the following formula:
where A0 was the absorbance of the control (blank, without compounds) and At was the
Absorbance in the presence of the compounds. All the tests were performed in triplicate and the
graph was plotted with the mean values.
Ferric reducing antioxidant power (FRAP) assay69 :
FRAP assay is based on the ability of antioxidants to reduce Fe3+ to Fe2+ in the presence
of 2,4,6-tri(2-pyridyl)- s-triazine (TPTZ), forming an intense blue Fe2+-TPTZ complex with an
absorption  maximum  at  593  nm.  This  reaction  is  pH-dependent  (optimum  pH  3.6).  The
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absorbance decrease is proportional to the antioxidant content (Benzie and Strain, 1996). 0.2 ml
of the compound is added to 3.8 ml of FRAP reagent (10 parts of 300 mM sodium acetate buffer
at pH 3.6, 1 part of 10.0 mM TPTZ solution and 1 part of 20.0 mM FeCl3. 6H2O solution) and
the reaction mixture is incubated at 37°C for 30 min and the increase in absorbance at 593 nm is
measured. FeSO4 is used for calibration. The antioxidant capacity based on the ability to reduce
ferric  ions  of  sample is  calculated from the linear  calibration curve and expressed as  mmol
FeSO4 equivalents per gram of sample. BHT, BHA, ascorbic acid, quercetin, catechin or trolox
can be used as a positive control.
ANTI-FUNGAL SCREENING OF THE SYNTHESIZED COMPOUNDS
             BY DISC DIFFUSION METHOD
PROCEDURE
Preparation of Sabourands dextrose broth: 74,75
     Composition of Sabourands dextrose broth
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Specified  amount  of
dextrose and peptone was
taken along  with  1000ml  of
distilled water in a conical
flask and  heated  in  a  steam
bath to dissolve. The pH was maintained at 7.6 ± 0.2 and sterilized in an autoclave at 15 lb
pressure, 120°C for 15 minutes. The sterile medium was poured into the sterile Petri dish and
allowed to solidify. 
Preparation of plates:
Sabourands dextrose broth medium was prepared and transferred into sterile Petri plates
aseptically (thickness of 5-6mm). The plates were allowed to dry at room temp. The plates were
inverted to prevent condensate falling on the agar surface. The layers of the medium are uniform
in thickness, is done by placing the plates on a leveled surface. Standardized fungal inoculums of
Aspergillus niger, Aspergillus fumigatus, Aspergillus parasiticus, Candida albicans, were applied
to  the  plates  and  spreaded  uniformly  over  the  surface  of  medium by  using  a  sterile  Non-
absorbent cotton swab and finally the swab was passed around the edge of the medium. The
inoculated plates were closed with the lid and allowed to dry at room temperature. The sample
impregnated  discs  (10µg /disc)  in  dimethyl  sulphoxide and  standard  Clotrimazole  10µg/disc
were placed on the inoculated agar medium. All petriplates were incubated at 27˚C -28˚C for 24
hrs. After the incubation diameter of zone of inhibition produced by the sample were measured.
Determination of Minimum Inhibitory Concentration for Synthesized Compounds (MIC)
by Serial dilution method:
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1 Dextrose 40g
2 peptone 10g
3 water 1000ml
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 The serial dilutions of known concentration of compound solution are made from the
stock  (100  mg/ml)  by  using  Sabourands  dextrose  broth  using  the  method  described
below.
 The tubes were labeled 1 to 8 and 1 ml of Sabourands dextrose broth were added to the
first 5 tubes and 8th tube, then added 0.5ml of  Sabourands dextrose broth  to  6th and 7th
tubes. 
 One ml of different synthesized compounds was added to the 1st tube, mixed and transfer
1ml serially up to tube 5.From the 5th tube transfer 1ml to 6th tube. Mixed and transfer
0.5 ml to the 7th tube. Each tube, 1 to 7 contains 1ml diluted extract.
 The 8th tube was the control. 
 With a standardized micro pipette, add a drop of the diluted broth culture approximately
0.01ml of the test organism to all tubes, including the control, gently mixed and incubated
at 26-28 0 c for 18 to 24hrs.
 The highest  dilution of particular compounds showing no turbidity was observed and
recorded. This was taken as the end point, and this dilution was considered to contain the
concentration of drug equivalent to MIC.
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Table 4: PHYSICOCHEMICAL PARAMETERS OF SYNTHESIZED DERIVATIVES
CODE MOLECULAR
FORMULA
MOLECULAR
Wt (g)
MP  (0C) % YIELD Rf log P COLOUR SOLUBILITY
A1 C10H18N2O2 198 91 – 93 45% 0.7 0.83 Pale yellow water
A2 C16H22N2O3 290 220 – 222 38.4% 0.62 2.92 yellow water
A3 C15H20N2O2 260 216 - 218 51% 0.81 2.24 Pale yellow water
A4 C17H22N2O2 286 191 – 193 61% 0.54 2.76 white water
A5 C15H19ClN2O2 294 216 – 218 48% 0.62 2.8 green water
A6 C17H25N3O2 303 241 – 243 57% 0.68 2.35 black water
B1 C16H22N2O2 274 185 – 187 68% 0.5 2.69 white DMSO
B2 C22H26N2O3 369 231 – 234 65% 0.78 3.96 yellow DMSO
B3 C21H24N2O2 336 246 – 248 48% 0.6 4.08 Pale green DMSO
B4 C23H26N2O2 362 238 – 240 52.5% 0.74 4.6 orange DMSO
B5 C22H26ClN2O2 385 276 – 279 74% 0.84 4.64 green DMSO
B6 C22H26ClN2O2 385 269 – 272 69% 0.48 4.45 green DMSO
B7 C23H29N3O2 379 274 – 276 89% 0.81 3.73 red DMSO
B8 C21H24N2O3 352 283 – 285 56% 0.52 3.69 brown DMSO
*Mobile phase – methanol: chloroform (1:1)
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Table 5: SPECTRAL DATA OF THE SYNTHESIZED COMPOUNDS
Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   
(m/z, amu)
A6
                   
1599(C=C ar)
840(di sub ben)
1240.04(c-o-c str)
1400.04 (methyl)
1542.1(C=N) 
0.9(s, 3H, CH3)
2.4-2.9(t, 2H, CH2)
2.8(d, 1H, CH)
1.0(t, 4H, CH3)
6.5-6.9(d,4H, Ar)
A2 1602(C=C ar)
1266.04(c-o-c str)
1401.04 (methyl)
1596(C=N)
1725(keto) 
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Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   
(m/z, amu)
A3 1602(C=C ar)
696(mono sub ben)
1266.04(c-o-c str)
1401.04 (methyl)
1788.65(ketone)
1552.1(C=N)
A4 1604(C=C ar)
690 (mono sub ben)
1294.97 (c-o-c str)
1400 (methyl)
1793.47(ketone)
1650.77(C=C ali)
1502.1(C=N)
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Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   
(m/z, amu)
A5 1602(C=C ar)
860(di sub ben)
1266.04(c-o-c str)
1401.04 (methyl)
1450.01(C-Cl)
1562.1(C=N)
A1 1597(C=C ar)
1292.04(c-o-c str)
1399(methyl)
1597.3(C=N)
1640(ketone)
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Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   
(m/z, amu)
B7 1638(C=C)
1262(C-O-C) 
1401 (CH3)
1638(C=N) 
1785(keto)
3128(Ar-H) 
831(di sub ben)
2.4-2.9(t, 3H, CH2)
2.8(d, 1H, CH)
1.0(t, 4H, CH3)
6.5-6.9(d,4H, Ar)
Mol. Ion
378.2
Base peak
252
B2 1265(C-O-C)
1590.1(C=N)
1400.01(OCH3)
1664(keto)
830.31(di sub ben)
Mol. ion 369
Base peak
252
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Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   
(m/z, amu)
B3 1161.85(C-O-C)
1552.1(C=N)
1400.01(CH3)
1642(keto)
697(mono sub ben)
2.4-2.9(t, 2H, CH2)
3.4(d, 1H, CH)
0.897(t, 2H, CH3)
7.0-8.5(d,10H, Ar)
2.6(d,1H,CH2)
B4 1298.85(C-O-C)
1550.1(C=N)
1650(keto)
691(mono sub ben)
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Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   (m/z,
amu)
B5 1298(C-O)
1592.1(C=N)
1402(C-Cl)
1794(keto)
863(di sub ben)
690(mono sub ben)
B6 1282(C-O-C)
1547.1(C=N)
1794(keto)
862(di sub ben)
1436.07(C-Cl) 
3.4(t, 2H, CH2)
2.8(d, 1H, CH)
1.91(t, 2H, CH3)
7.0-8.0(d,9H, Ar)
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Comp.
code 
Molecular structure (IR) υmax (KBr/cm-1) NMR (δ ppm) MASS   (m/z,
amu)
B1 1264.85(C-O-C)
1552.1(C=N)
1400.01(CH3)
1648(keto)
693.31(mono sub ben)
 
B8 1208.85(C-O-C)
1602(C=N)
1652(keto)
831(di sub ben)
3120(OH)
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Table 6:Anti-Diabetic activity of synthesized compounds
S.NO CODE IC50   at 10µM
1 A1 69%
2 A2 10%
3 A3 8%
4 A4 13%
5 A5 16%
6 A6 85%
7 B1 84%
8 B2 19%
9 B3 14%
10 B4 12%
11 B5 31%
12 B6 12%
13 B7 70%
14 B8 10%
15 pioglitazone 79%
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Anti Oxidant activity of synthesized compounds
INVITRO ANTIOXIDANT 
DPPH RADICAL SCAVENING ACTIVITY:
DPPH  Radical  scavenging  (antioxidant)  activity  was  determined  by  the  method
modified by Hatano et al., (1989).
Table 9:
Percentage of inhibition
Conc A1 A3 A6 B1 B4 B5 B7 Ascorbicacid
25µg 63.42 78.26 46.99 54.97 61.8 65.5 48.09 46.7
50µg 63.2 81.26 74.48 63.24 65.9 68.9 59.1 68.9
75µg 62.92 82.41 82.18 64.52 65.6 73.08 75.98 89
100µg 62.84 83.5 83.9 65.19 69.4 76.79 78.21 96
EC 50 11±0.12* - 29±0.9* 15±0.47 18±0.61 - 24±0.94 22±0.45
ANTIOXIDANT ACTIVITY OF COMPOUNDS A1, A3, A6, B1, B4, B5, B7 AND 
ASCORBIC ACID:
FRAP Method:
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Table 10:
Absorbance
Conc
A1 A3 A6 B1 B4 B5 B7
Ascorbicacid
25µg
1.97 3.98 3.95 3.93 3.89 3.86 3.71 3.45
50µg
1.61 3.89 3.92 3.79 3.7 3.72 3.42 2.85
75µg
1.03 3.84 3.9 3.53 3.66 3.39 3.24 2.35
100µg
0.91 3.85 3.87 3.54 3.66 3.47 3.04 1.89
r2
0.94 0.74 0.98 0.88 0.73 0.78 0.98 0.9962
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                                                                           Table 7: Anti-fungal activity of the synthesized compounds
Sl.no Micro organisms
                                                                  Zone of inhibition(in mm) 
                                                                  Compounds(10 µg/disc)
A-1
(1)
A-2
(2)
A-3
(3)
A-4
(4)
A-
5
(5)
A-
6
(6)
B-1
(7)
B-2
(8)
B-3
(9)
B-4
(10)
B-5
(11)
B-6
(12)
B-7
(13)
B-8
(14)
STD Clotrimazole
10µg/disc
1 Aspergillus
fumigalis
3 10 3 - 6 3 - 3 - 8 7 8 - - 15
2 Candida albicans 8 12 8 12 3 - - - 12 - 5 3 - - 12
3 Streptomyces
griseus
4 5 3 4 3 4 3 3 6 6 9 10 - - 14
4 Monascus   ruber - - - 3 3 6 2 3 6 3 8 3 - - 15
K M C H College of Pharmacy  52
ANTI-FUNGAL SCREENING
                   Chapter 4                                                                                                                                                 Results and discussion
      
 Table 8. MIC values of the synthesized compounds 
Sl.no microorganisms MIC VALUES (µg/ml)
A-1
(1)
A-2
(2)
A-3
(3)
A-4
(4)
A-5
(5)
A-6
(6)
B-1
(7)
B-2
(8)
B-3
(9)
B-4
(10)
B-5
(11)
B-6
(12)
B-7
(13)
B-8
(14)
1 Aspergillus
fumigatus 5.0 1.25 5.0 10 2.5 5.0 10 5.0 10 0.62
5
1.25 1.25 10 10
2 Candida albicans
2.5 1.25 6..25 1.25 10 - - - 1.25 - 2.5 2.5 - -
3 Streptomyces
griseus 10 5.0 10 10 10 10 10 10 5.0 2.5 2.5 1.25 - -
4 Monascus  ruber
- - - 10 10 5.0 10 10 5.0 10 2.5 10 - -
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Provoked by the biological activity of the oxazolone and in view of ongoing search for
the most potent anti-diabetic, anti-oxidant and anti-fungal agent, some novel 2, 3 Disubstituted
derivatives of oxazolone have been synthesized and their anti-diabetic,  anti-oxidant and anti-
fungal activity studied.
Synthesis of designed oxazolone analogues:
This involves a three step procedure from a commercially available starting material
Step 1: This step involves acetylation of amino acid glycine by using acetylating agent Acetic
anhydride to form acetylglycine with 75% yield. The acetic anhydride reacted with amino group
which  leads  to  the  elimination  of  hydrogen  atom,  and  then  the  acetyl  group  replaces  the
hydrogen atom of amino group.
Step 2: This step involves cyclization of acetyl glycine with acetic anhydride in the presence of
sodium acetate in to 2-methyl oxazole-5-one, followed by reaction of the active methylene group
with aldehydes to afford the corresponding benzylidine derivatives. 
Step 3: This step involves Michael addition of oxazolone derivatives by using diethylamine as a
reactant  and ceric  ammonium nitrate as a catalyst.  The diethylamino group reacted with the
active hydrogen atom in the oxazolone derivative.
All the derivatives of oxazolone (A1-A6 and B1-B8) were obtained with good yield. The
percentage yield was found to be in the range of 60% - 80%. 
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CHARACTERIZATION OF SYNTHEZISED COMPOUNDS
The physicochemical parameters like, molecular weight, log P, solubility, melting point,
and Rf of the synthesized compounds were determined.
The melting points of the synthesized compounds determined and were uncorrected, and
melting range was found to be between, 280-2400C
The purity of the synthesized compounds was established by single spot on the TLC Plate
(mobile phase- Chloroform and methanol in 1:1 ratio) and all the compounds found to be pure. 
 The structures of the synthesized compounds were confirmed by  IR, NMR, and mass
spectral analysis. 
IR Spectrum of the synthesized compounds showed the characteristic absorption band at
1480-1498cm-1  bands       (C=N respectively), 1620-1650 cm-1due to C=O stretching vibration,
1400 cm-1due to CH stretching,  1260-1280cm-1 due to C-O strtching  confirms the chemical
structure of the oxazolone derivatives.
PMR spectra  of  the synthesized oxazolone derivative  shows 4 aromatic  protons  as  a
doublet in 6.9-7.6 ppm, 3 Protons of methyl group appeared at 0.9 ppm as a singlet, and  1
Protons of ethyl link appeared as a singlet in 4.5 ppm . Thus the proton magnetic spectrum of the
compound was in full agreement with its molecular formula, with regard to proton count and the
chemical shift also.
 The Mass Spectral analysis of the synthesized compounds B4 and B6   were  performed,
and the mass spectrum of the compound was in agreement with its molecular weight.
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BIOLOGICAL SCREENING
ANTI-DIABETIC ACTIVITY
The anti-diabetic studies were carried out with all synthesized oxazolone derivatives in
the  concentration  10µg/ml,  in  DMSO  against  Aldose  reductase  enzyme  by  using  enzyme
inhibition assay. Pioglitazone of same concentrations was used as standard. The anti-diabetic
activities of the compounds were evaluated by estimation of IC 50 value. It could be seen that
acetaldehyde(A1 and B1) and dimethylamino benzaldehyde (A6 and B7)derivatives exhibit good
anti-diabetic activity. The IC 50 values of the A1, A6, B1and B7 were found to be 69%,85%,84%
and 79% and the standard IC 50 was found to be 79%. 
It is clear from the results that the anti-diabetic potential of compounds associated with
the position of the substituent on 4th position. Compound A6 , B7 having dimethyl amino group
and  Compound A1 , B1 having methyl group, shown higher activity than the other substituents
having compound. 
Compound  A6   4-((diethylamino)(4-(dimethylamino)phenyl)methyl)-2-methyloxazol-
5(4H)-one showed  excellent activity among the other compounds. When compared to standard
Pioglitazine  Compound  A6 shown  comparable  activity,  where  as  other  compounds  shown
slightly lesser activity than pioglitazone. 
ANTI – OXIDANT ACTIVITY
The synthesized compounds were tested for anti-oxidant activity by DPPH assay method
at the concentration of 25µg/ml, 50µg/ml, 75µg/ml and 100µg/ml in DMSO.  Ascorbic acid was
used as standard. Compounds A6, B1 and B7 were shown good anti oxidant activity with EC-
50 value of 29±0.9*, 15±0.47*,18±0.61* and 24±0.94*.
The synthesized compounds were tested for anti-oxidant activity by FRAP Assay method
at the concentration of 25µg/ml, 50µg/ml, 75µg/ml and 100µg/ml in DMSO.  Ascorbic acid was
used as  standard.  Compounds  A1,  A6 and B7  were  shown good anti  oxidant  activity with
linearity 0.94,0.98 and 0.98, the linearity of standard Ascorbic acid was found to be 0.996. 
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From the results  it  is  clear  that  the compounds having dimethyl  amino and methoxy
groups at 4th position  shown good activity when compared with standard ascorbic acid.
ANTI- FUNGAL ACTIVITY
Evaluation of the results from anti-fungal studies showed that synthesised  derivatives
exhibits  moderate  to  good  anti-fungal  activity  against  Aspergillus  fumigatus,  Streptomyces
griseus, Aspergillus niger, Candida albicans, With zone of inhibition range (8-15mm).
The compounds A2, B3 and B6 are showed moderate to good activity against Aspergillus
fumigatus, Streptomyces griseus, Aspergillus niger, Candida albicans,  as compare to standard
Clotrimazole With zone of inhibition (8-15mm). 
The  compound  A2,  A4 shown  excellent  activity  on Candida  albicans  with  zone  of
inhibition (12mm).
The  MIC  of  the  synthesized  compounds  against Aspergillus  fumigatus,  streptomyces
griseus, Aspergillus niger, Aspergillus parasitus, Candida albicans determined by serial dilution,
was found to be in the range of 0.625-5.0µg/ml.
Among  the  synthesized  compounds  4-((diethylamino)(4-methoxyphenyl)methyl)-2-
methyloxazol-5(4H)-one  (A2),  4-(1-(diethylamino)-3-phenylallyl)-2-methyloxazol-5(4H)-one
(A4), shown excellent activity on Candida albicans. From this it is clear that 2-methyl oxazole
compounds are more active than the 2-benzyl oxazole compounds. The activity of A2 is may be
because of methoxy  substituent at 4th position and A4 is may be because of the presence  allyl
group.
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Some novel oxazolone derivatives were synthesized to get more potent drug for the
treatment of Diabetes and other fungal infectious diseases. 
The structures of the synthesized compounds were confirmed by spectral analysis.
The synthesized oxazolone derivatives exhibited good anti-diabetic,  anti-oxidant and anti-
microbial activity, among those Compounds A1, A6, B1 and B7 were found to be the most
potent  compound  with  Promising  activity  against  Aldose  reductase  enzyme  which  is
responsible for Diabetes and its complications, as well as Compound A1, A6 and B7 were
found to be  good Anti-Oxidant agents and Compound A2 was found to be  a potent anti-
fungal agent. Since the compounds synthesized shows good Anti-Diabetic, Anti- Oxidant and
Anti-  Fungal  activity.  So  the  developed  compounds  will  be  useful  for  adjuvant
pharmacotherapy  of  Diabetes  and  its  complications  along  with  other  fungal  infectious
diseases in Diabetic patients.
Further studies on its possible mechanism and in-vivo trials on experimental animals
to  broaden  their  Pharmacological  assessment  may  provide  a  potent  analogue  that  can
overcome adverse effects involved in the treatment of diabetes and will enhance the quality
of life of diabetic patients due to its antioxidant and antifungal property. 
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